Carisma Therapeutics Inc., a clinical-stage biopharmaceutical company listed on Nasdaq (CARM), has announced significant changes to its Board of Directors. Effective June 30, 2024, Marella Thorell, the CFO of Seres Therapeutics, and David Scadden, M.D., a renowned Harvard Medical professor, joined the board. Concurrently, Regina Hodits and Bjorn Odlander have stepped down due to other professional commitments. The addition of Thorell and Scadden is expected to bolster Carisma’s efforts in developing innovative immunotherapies, particularly in the field of engineered macrophages. Thorell brings extensive financial and operational expertise from her experience at multiple biotech firms, while Dr. Scadden adds significant scientific and medical credentials, including his affiliations with Harvard Stem Cell Institute and Massachusetts General Hospital. The changes aim to enrich the board’s diversity and expertise, as Carisma continues to advance its cell therapy platform focused on treating cancer and serious diseases.

Biopharmaceuticals, Biotechnology, Healthcare,United States

Carisma Therapeutics Announces Changes to its Board of Directors